Evaluation of Retinal and Vascular Features in Macular Degeneration After Intravitreal Injections of Bevacizumab

Federico II University

Status: Completed

Conditions: Exudative Age-related Macular Degeneration

Treatments: Drug: Bevacizumab Injection

Study type: Observational

Funder types: Other

Identifiers

NCT04138420

PT1124/14

Details and patient eligibility

About

This study evaluates the retinal and vascular features in patients with macular degeneration under the effects of Bevacizumab intravitreal injections using optical coherence tomography and optical coherence tomography angiography.

Full description

Bevacizumab is a vascular endothelial growth factor antagonist represent an efficacy treatment for exudative age-related macular degeneration acting on vascular hyperpermeability.

The optical coherence tomography and optical coherence tomography angiography represent novel and non-invasive diagnostic techniques that allow a detailed and quantitative analysis of retinal and vascular features.

The study evaluates the changes in optical coherence tomography and optical coherence tomography angiography parameters at baseline and after three monthly injections of Bevacizumab in exudative AMD.

Enrollment: 38 patients

Sex: All

Ages: 50 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• age older than 50 years, diagnosis of exudative age-related macular degeneration, treatment-naïve with Bevacizumab for exudative age-related macular degeneration.

Exclusion criteria

• age younger than 50 years, diagnosis of exudative macular degeneration due to other causes, previous treatments before Bevacizumab for exudative age-related macular degeneration.

Trial design

38 participants in 1 patient group

Patients receiving Bevacizumab

Description:

Bevacizumab, intravitreal injection, three monthly, dosage: 1.25 mg/0.05 mL.

Treatment:

Drug: Bevacizumab Injection